Biodexa tops 50% enrollment in Serenta Phase 3 FAP trial of eRapa

Biodexa reported recruitment passed the halfway mark in its registrational Phase 3 Serenta trial of eRapa in familial adenomatous polyposis.

Results have not been presented; the next readout is a planned futility analysis, with a later database lock to support final evaluation.

The update signals progress toward a pivotal efficacy assessment, a key step toward potential commercialization in a rare gastrointestinal cancer risk condition.

Enrollment reached 87 of 168 planned subjects, with recruitment running across 29 U.S. and European clinical sites.